Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2

The Neurofibromatosis 2 Tumor Suppressor Gene Product, Merlin, Regulates Human Meningioma Cell Growth by Signaling through YAP

(2015) Katherine Striedinger et al.   NEOPLASIA

Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients

(2013) Fabio P. Nunes et al.   PLoS One

Antiangiogenic Agents for Nonmalignant Brain Tumors

(2013) Joshua Rubin et al.   Journal of Neurological Surgery Part B-Skull Base

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

(2012) Matthias A. Karajannis et al.   NEURO-ONCOLOGY

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

(2012) Scott R. Plotkin et al.   OTOLOGY & NEUROTOLOGY

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab

(2011) S. Goutagny et al.   ANNALS OF ONCOLOGY

Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside

(2011) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation

(2010) V.- F. Mautner et al.   ANNALS OF ONCOLOGY

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

(2010) Hon Kit Wong et al.   CANCER RESEARCH

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

(2009) Scott R. Plotkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Experience With Radiation Therapy in the Management of Neurofibromatosis-Associated Central Nervous System Tumors

(2008) Stacy Wentworth et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS